跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 71,889 条关于
“higher-risk myelodysplastic syndrome”
全部
71,889
临床试验
55,170
药物
357
机构
81
资讯
16,281
去年
Syros' Tamibarotene Fails Phase III Trial in Higher-Risk Myelodysplastic Syndrome
去年
Syros' Tamibarotene Fails in Phase III Trial for Higher-Risk Myelodysplastic Syndrome
去年
Syros' Tamibarotene Fails in Phase III Trial for Higher-Risk Myelodysplastic Syndrome
去年
Tamibarotene Fails to Meet Primary Endpoint in SELECT-MDS-1 Trial for Higher-Risk Myelodysplastic Syndrome
去年
AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint
去年
Ipilimumab and Nivolumab Show Promise in Higher-Risk Myelodysplastic Syndromes
上个月
Faron Reports Encouraging First Overall Survival Data for Bexmarilimab in Frontline HR-MDS, Median OS Not Yet Reached in Key Subgroups
去年
Syros Pharmaceuticals Announces SELECT-MDS-1 Trial Update and Strategic Realignment
去年
Study Reveals Significant Treatment Disparities in High-Risk Myelodysplastic Syndrome Patients
去年
Cullgen Completes Phase 1 Enrollment for Novel Non-Opioid Pain Therapy CG001419
第 1 页，共 1629 页
上一页
下一页
